

Victhom Human Bionics Inc.
(formerly Begama Technologies Inc.)

**Interim Financial Statements
at September 30, 2002**

Victhom Human Bionics Inc.

(formerly Begama Technologies Inc.)

Operations

Initial eight-and-a-half month period ended September 30, 2002
(unaudited)

	Three months - and-a-half ended September 30 \$	Eight months - and-a-half ended September 30 \$
Expenses		
Administrative expenses	5,845	16,600
Financial expenses	23	68
Net loss	5,868	16,668
Weighted average number of common shares outstanding	3,933,333	3,151,047
Basic and diluted net loss per share	(0,001)	(0,005)

The accompanying notes are an integral part of the interim financial statements.

Victhom Human Bionics Inc.

(formerly Begama Technologies Inc.)

Deficit

Initial eight-and-a-half month period ended September 30, 2002

(unaudited)

	At September 30, 2002 \$
	<u> </u>
Balance , beginning of period	-
Net loss	16,668
Balance , end of period	<u><u>16,668</u></u>

The accompanying notes are an integral part of the interim financial statements.

Victhom Human Bionics Inc.

(formerly Begama Technologies Inc.)

Cash flows

Initial eight-and-a-half month period ended September 30, 2002
(unaudited)

	Three months - and-a-half ended September 30 \$	Eight months - and-a-half ended September 30 \$
OPERATING ACTIVITIES		
Net loss	(5,868)	(16,668)
Non-cash items		
Changes in working capital (Note 3)	52,295	(49,766)
Cash flows from operating activities	46,247	(66,434)
INVESTING ACTIVITIES		
Deferred costs and cash flows from investing activities	(144,168)	(215,492)
FINANCING ACTIVITIES		
Issuance of shares		307,000
Issuance fees		(44,031)
Cash flows from financing activities	-	262,969
Net decrease in cash	(97,741)	(18,957)
Cash, beginning of period	198,784	120,000
Cash, end of period	101,043	101,043

The accompanying notes are an integral part of the interim financial statements.

Victhom Human Bionics Inc.
(formerly Begama Technologies Inc.)
Balance Sheet

	September 30, 2002 (unaudited)	Opening as at January 12, 2002 (audited)
	<u>\$</u>	<u>\$</u>
ASSETS		
Current assets		
Cash	101,043	120,000
Accounts receivable (Note 4)	133,688	
	332,472	120,000
Deferred costs (Note 5)	215,492	
	450,223	120,000
	<u>450,223</u>	<u>120,000</u>
LIABILITIES		
Current liabilities		
Accounts payable and accrued liabilities	83,922	
SHAREHOLDERS' EQUITY		
Capital stock (Note 5)	382,969	120,000
Deficit	(16,668)	
	366,301	120,000
	450,223	120,000
	<u>450,223</u>	<u>120,000</u>

The accompanying notes are an integral part of the interim financial statements.

On behalf of the Board,

....., Director

....., Director

Victhom Human Bionics Inc.

(formerly Begama Technologies Inc.)

Supplementary Information

Initial eight-and-a-half month period ended September 30, 2002

1 – GOVERNING STATUTES AND NATURE OF OPERATIONS

The Company, incorporated January 11, 2002 under the Canada Business Corporation Act, is classified as a capital pool company as defined in the TSX Venture Exchange Policy.

2 – ACCOUNTING POLICIES

Unaudited interim financial statements

The accompanying financial statements for the initial eight-and-a-half month period ended September 30, 2002 are unaudited. These unaudited financial statements have been prepared in the same basis as the audited opening balance sheet, on which an auditor's report has been signed on January 17, 2002. In the opinion of management, all adjustments, consisting of normal recurring adjustments, necessary for a fair presentation of the financial position, results of operations and cash flows for the period presented.

Deferred costs

Deferred costs will be transferred to capital stock when the qualifying transaction is realized.

3 – INFORMATION INCLUDED IN THE STATEMENT OF EARNINGS

The changes in working capital items are detailed as follows :

	<u>\$</u>
Accounts receivable	(133,688)
Accounts payable and accrued liabilities	<u>83,922</u>
	<u>(49,766)</u>

4 – ACCOUNTS RECEIVABLE

	<u>\$</u>
Taxes	8,688
Due from Victhom Corporation, without interest	<u>125,000</u>
	<u>133,688</u>

Victhom Human Bionics Inc.

(formerly Begama Technologies Inc.)

Supplementary Information

Initial eight-and-a-half month period ended September 30, 2002

5 – DEFERRED COSTS

The deferred costs are detailed as follows :

	<u>\$</u>
Legal fees	169,683
Financing fees	16,046
Professionals fees	13,200
Others	16,563
	<u>215,492</u>

6 – CAPITAL STOCK

Authorized

Unlimited number of common shares without par value, voting and participating

Issued and fully paid

The following table illustrates changes in the Company's capital stock during the period:

	<u>Number</u>	<u>Amount</u>
		<u>\$</u>
Issued for cash on January 12, 2002	1,600,000 (1)	120,000
Issued for cash on March 15, 2002	133,333 (1)	10,000
Issued for cash on April 11, 2002	2,200,000 (1)	297,000
Issuance fees		(44,031)
Balance as at June 30, 2002	<u>3,933,333</u>	<u>382,969</u>

(1) A total of 1,821,333 common shares are subject to an escrow agreement and may not be transferred, assigned or otherwise dealt with without the consent of the regulatory authorities.

7 – SUBSEQUENT EVENTS

On May 21, 2002, Victhom Corporation signed a letter of intent with the Company according to which the latter will buy all the issued and outstanding shares of Victhom Corporation. The transaction is subject to approval by the Alberta Securities Commission, the Quebec Securities Commission and the TSX Venture Exchange and a majority of minority shareholders of the Company.

Under the transaction, Victhom Corporation would receive such a number of shares of the Company as to give way to a reverse takeover by the Company. The Company signed a letter of intent with Canaccord Capital Corporation for a public offering of a minimum of \$2,400,000 and a maximum of \$3,000,000 at a \$0,50 per share.

A portion of the funds raised will be used in research and development and to purchase specific equipment regarding the research and development. The balance will be used for solicitation to develop strategic alliances and the working capital.

Victhom Human Bionics Inc.

(formerly Begama Technologies Inc.)

Supplementary Information

Initial eight-and-a-half month period ended September 30, 2002

8 – STOCK-BASED COMPENSATION

On April 11, 2002, the Company granted stock options for a total of 350,000 common shares to two independent directors at an exercise price of \$0.15. The options granted can be exercised over a period of five years beginning on their grant date. The Company does not record any compensation expense in earnings when the options are granted. Had the compensation expense for the stock options granted been determined using the fair value-based method at the grant date, the Company's net loss and the net loss per share figures for the eight-and-a-half month periods ended June 30, 2002 would have been the following pro forma amounts:

	Five-and-a-half period ended September 30, 2002
	\$
Net loss	
As reported	16,668
Pro forma	55,168
Net loss and diluted net loss per share	
As reported	(0,005)
Pro forma	(0,005)

The fair value of the options granted during the quarter ended September 30, 2002 is estimated at \$0.11 per option. The fair value of these options was determined at the grant date using the Black-Scholes option pricing model considering the following assumptions:

Risk-free interest rate	5,16%
Expected life (in years)	5
Expected share volatility	90%
Expected dividends	0